Want to see GB:IMM full AI Analyst Report?
IMM Stock Chart & Stats
6.20 p
0.95 p(79.03%)
At close: 4:00 PM EST
6.20 p
0.95 p(79.03%)
Day’s Range― - ―
52-Week Range1.39 p - 19.40 p
Previous CloseN/A
Volume11.77M
Average Volume (3M)15.00M
Market Cap
£20.78M
Enterprise Value18.98M
Total Cash (Recent Filing)£1.35M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding623,911,400
10 Day Avg. Volume4,827,745
30 Day Avg. Volume14,996,625
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)44.28
Price to Sales (P/S)0.00
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageReported debt near zero is a durable structural strength: it lowers bankruptcy and interest-service risk, preserves financing optionality, and gives management flexibility to fund clinical programs or pursue partnerships without immediate debt constraints. This reduces short-term leverage risk over a 2–6 month horizon.
Improving Cash Flow TrendAn improving free cash flow trend, even from negative levels, indicates progress in cost control or timing of spend. For a clinical-stage biotech, a sustained reduction in cash burn improves runway and reduces near-term financing frequency, supporting more stable development progress over several months.
Narrowing LossesProgressive narrowing of net losses reflects structural cost reduction or greater operational efficiency. Sustained margin improvement at the operating-loss level can extend runway, make the company a more attractive partner or acquirer, and materially lower dilution risk if maintained over the medium term.
Bears Say
No Product RevenueA multi-year absence of product revenue is a fundamental weakness for durability: it means the business lacks operating cash generation and is dependent on external financing or deals. Without imminent commercialization, revenue risk remains structural and affects sustainability over 2–6 months.
Persistent Cash BurnConsistently negative operating cash flow (about -2.37M in 2025) signals ongoing cash consumption by operations. For a small clinical-stage firm, continued burn creates recurring financing need, increasing dilution risk and potentially forcing program prioritization or delays if external funding is constrained.
Fragile Capital BaseVolatile equity that turned negative reflects a thin and fragile capital structure. That instability raises the likelihood of equity raises, restructurings, or unfavorable financing terms, which can dilute existing holders and constrain strategic choices across the medium term.
ImmuPharma News
IMM FAQ
What was ImmuPharma PLC’s price range in the past 12 months?
ImmuPharma PLC lowest share price was 1.39 p and its highest was 19.40 p in the past 12 months.
What is ImmuPharma PLC’s market cap?
ImmuPharma PLC’s market cap is £20.78M.
When is ImmuPharma PLC’s upcoming earnings report date?
ImmuPharma PLC’s upcoming earnings report date is Sep 24, 2026 which is in 83 days.
How were ImmuPharma PLC’s earnings last quarter?
ImmuPharma PLC released its earnings results on May 27, 2026. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.
Is ImmuPharma PLC overvalued?
According to Wall Street analysts ImmuPharma PLC’s price is currently Overvalued.
Does ImmuPharma PLC pay dividends?
ImmuPharma PLC pays a Notavailable dividend of 1 p which represents an annual dividend yield of N/A. See more information on ImmuPharma PLC dividends here
What is ImmuPharma PLC’s EPS estimate?
ImmuPharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmuPharma PLC have?
ImmuPharma PLC has 623,911,400 shares outstanding.
What happened to ImmuPharma PLC’s price movement after its last earnings report?
ImmuPharma PLC reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -4.333%.
Which hedge fund is a major shareholder of ImmuPharma PLC?
Currently, no hedge funds are holding shares in GB:IMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Technical Analysis
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
SkinBioTherapeutics
―
Poolbeg Pharma Ltd.
―